Next Article in Journal
Ionotropic Gelation and Chemical Crosslinking as Tools to Obtain Gellan Gum-Based Beads with Mesalazine
Next Article in Special Issue
Feasibility of Hot Melt Extrusion in Converting Water-Based Nanosuspensions into Solid Dosage Forms
Previous Article in Journal
Food Effect and Formulation: How Soluble Fillers Affect the Disintegration and Dissolution of Tablets in Viscous Simulated Fed State Media
Previous Article in Special Issue
Enhancing Patient-Centric Drug Development: Coupling Hot Melt Extrusion with Fused Deposition Modeling and Pressure-Assisted Microsyringe Additive Manufacturing Platforms with Quality by Design
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Process Development for the Continuous Manufacturing of Carbamazepine-Nicotinamide Co-Crystals Utilizing Hot-Melt Extrusion Technology

1
Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China
2
Pharmaceutical Products Research and Development Center, Marine Biomedical Research Institute of Qingdao, Qingdao 266137, China
3
Material Characterization, Thermo Fisher Scientific, Shanghai 201203, China
*
Author to whom correspondence should be addressed.
Pharmaceutics 2025, 17(5), 568; https://doi.org/10.3390/pharmaceutics17050568
Submission received: 15 March 2025 / Revised: 18 April 2025 / Accepted: 21 April 2025 / Published: 25 April 2025
(This article belongs to the Special Issue Advances in Hot Melt Extrusion Technology)

Abstract

Objectives: Hot-melt extrusion (HME) offers a solvent-free, scalable approach for manufacturing pharmaceutical co-crystals (CCs), aligning with the industry’s shift to continuous manufacturing (CM). However, challenges like undefined yield optimization, insufficient risk management, and limited process analytical technology (PAT) integration hinder its industrial application. This study aimed to develop a proof-of-concept HME platform for CCs, assess process risks, and evaluate PAT-enabled monitoring to facilitate robust production. Methods: Using carbamazepine (CBZ) and nicotinamide (NIC) as model compounds, an HME platform compatible with PAT tools was established. A systematic risk assessment identified five key risk domains: materials, machinery, measurement, methods, and other factors. A Box–Behnken design of experiments (DoE) evaluated the impact of screw speed, temperature, and mixing sections on CC quality. Near-infrared (NIR) spectroscopy monitored CBZ-NIC co-crystal formation in real time during HME process. Results: DoE revealed temperature and number of mixing sections significantly influenced particle size (D50: 2.0–4.0 μm), while screw speed affected efficiency. NIR spectroscopy detected a unique CC absorption peak at 5008.3 cm⁻¹, enabling real-time structural monitoring with high accuracy (R² = 0.9999). Risk assessment highlighted material attributes, process parameters, and equipment design as critical factors affecting CC formation. All experimental batches yielded ≥ 94% pure CCs with no residual starting materials, demonstrating process reproducibility and robustness. Conclusions: Overall, this work successfully established a continuous hot-melt extrusion (HME) process for manufacturing CBZ-NIC co-crystals, offering critical insights into material, equipment, and process parameters while implementing robust in-line NIR monitoring for real-time quality control. Additionally, this work provides interpretable insights and serves as a basis for future machine learning (ML)-driven studies.
Keywords: hot-melt extrusion; co-crystal; continuous manufacturing; process analytical technology tools; risk assessment; Box–Behnken design hot-melt extrusion; co-crystal; continuous manufacturing; process analytical technology tools; risk assessment; Box–Behnken design

Share and Cite

MDPI and ACS Style

Huang, L.; Ni, W.; Jia, Y.; Zhu, M.; Yang, T.; Yu, M.; Zhang, J. Process Development for the Continuous Manufacturing of Carbamazepine-Nicotinamide Co-Crystals Utilizing Hot-Melt Extrusion Technology. Pharmaceutics 2025, 17, 568. https://doi.org/10.3390/pharmaceutics17050568

AMA Style

Huang L, Ni W, Jia Y, Zhu M, Yang T, Yu M, Zhang J. Process Development for the Continuous Manufacturing of Carbamazepine-Nicotinamide Co-Crystals Utilizing Hot-Melt Extrusion Technology. Pharmaceutics. 2025; 17(5):568. https://doi.org/10.3390/pharmaceutics17050568

Chicago/Turabian Style

Huang, Lianghao, Wen Ni, Yaru Jia, Minqing Zhu, Tiantian Yang, Mingchao Yu, and Jiaxiang Zhang. 2025. "Process Development for the Continuous Manufacturing of Carbamazepine-Nicotinamide Co-Crystals Utilizing Hot-Melt Extrusion Technology" Pharmaceutics 17, no. 5: 568. https://doi.org/10.3390/pharmaceutics17050568

APA Style

Huang, L., Ni, W., Jia, Y., Zhu, M., Yang, T., Yu, M., & Zhang, J. (2025). Process Development for the Continuous Manufacturing of Carbamazepine-Nicotinamide Co-Crystals Utilizing Hot-Melt Extrusion Technology. Pharmaceutics, 17(5), 568. https://doi.org/10.3390/pharmaceutics17050568

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop